Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) EBITDA (2016 - 2023)

Rapid Therapeutic Science Laboratories' EBITDA history spans 8 years, with the latest figure at -$103732.0 for Q2 2023.

  • For Q2 2023, EBITDA rose 19.2% year-over-year to -$103732.0; the TTM value through Jun 2023 reached -$547591.0, up 73.17%, while the annual FY2022 figure was -$1.3 million, 41.94% up from the prior year.
  • EBITDA for Q2 2023 was -$103732.0 at Rapid Therapeutic Science Laboratories, down from -$98294.0 in the prior quarter.
  • Across five years, EBITDA topped out at $27342.0 in Q4 2022 and bottomed at -$789393.0 in Q1 2022.
  • The 5-year median for EBITDA is -$372907.0 (2022), against an average of -$340544.1.
  • The largest annual shift saw EBITDA plummeted 2266.93% in 2020 before it surged 104.36% in 2022.
  • A 5-year view of EBITDA shows it stood at -$141867.0 in 2019, then crashed by 260.22% to -$511029.0 in 2020, then decreased by 22.74% to -$627240.0 in 2021, then soared by 104.36% to $27342.0 in 2022, then plummeted by 479.39% to -$103732.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's EBITDA are -$103732.0 (Q2 2023), -$98294.0 (Q1 2023), and $27342.0 (Q4 2022).